15+ Years at Wyss Institute at Harvard University      |      10+ Years in Pharmaceutical Development Industry

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Breaking down cancer cells to build a better vaccine? 🧫🧬 We previously found a clever way to improve personalized cancer immunotherapies. Traditionally, scientists use "tumor lysate" (broken down cancer cells) to teach the immune system what to fight. The problem? Lysate doesn't always trigger a strong immune response. Enter "Reduced Cancer Cells" (RCCs). In this study, we mechani

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies An animation to accompany our "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock" paper, where we describe the development of ciVAX (Composite Infection Vaccine), a modular, injectable biomaterial scaffold designed to provide broad-spectrum protection against lethal bacterial infections and sepsis. Full report @ https://is.gd/CzSnuk #sepsis

By Sasha Stafford | Principal Scientist & Founder | Elixis Biosciences & Prodelic Technologies Our "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock" paper describes the development of ciVAX (Composite Infection Vaccine), a modular, injectable biomaterial scaffold designed to provide broad-spectrum protection against lethal bacterial infections and sepsis. Full report @ https://is.gd/CzSnuk #sepsis #vaccines #Biomaterials #medtech #